Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Ripertamab in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (RIPERT-CIDP): a Randomised, Double-blind, Multicentre, Placebo-controlled Phase 3 Trial

NCT06858722 is registered in ClinicalTrials.gov with Zhongming Qiu as lead sponsor.

NCT NCT06858722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06858722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Ripertamab in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (RIPERT-CIDP): a Randomised, Double-blind, Multicentre, Placebo-controlled Phase 3 Trial
Lead sponsor
Zhongming Qiu
Phase
Phase 3
Overall status
Not yet recruiting
Start date
March 15, 2025
Completion date
December 31, 2027
Enrollment
175 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic inflammatory demyelinating polyneuropathy (cidp)